Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Xencor (XNCR)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Moderna (MRNA) and Xencor (XNCR).
Claim 30% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Moderna (MRNA)
In a report released today, Alec Stranahan from Bank of America Securities reiterated a Sell rating on Moderna, with a price target of $31.00. The company’s shares closed last Monday at $51.28, close to its 52-week low of $29.25.
According to TipRanks.com, Stranahan is a 4-star analyst with an average return of
Currently, the analyst consensus on Moderna is a Hold with an average price target of $36.13.
See Insiders’ Hot Stocks on TipRanks >>
Xencor (XNCR)
The company’s shares closed last Monday at $12.05, close to its 52-week low of $10.90.
According to TipRanks.com, Cheng is a 2-star analyst with an average return of
Currently, the analyst consensus on Xencor is a Strong Buy with an average price target of $24.72, which is a 102.5% upside from current levels. In a report issued on March 10, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $11.50 price target.
Read More on MRNA:
